Imricor Builds Regulatory and Clinical Momentum with US$7.8M Q1 Outflow

Regulatory Headway Sets Stage for US Market Expansion

Imricor Medical Systems (ASX:IMR) kicked off 2026 with pivotal FDA clearances for its NorthStar Mapping System and Vision-MR Diagnostic Catheter, laying a critical foundation for broader commercialisation in the US electrophysiology market. These approvals mark a major validation of Imricor’s real-time MR guidance platform and have already sparked strong inbound interest, with multiple customer quotes issued and initial sales expected in Q2.

Further regulatory progress includes the submission of the Advantage-MR EP Recorder/Stimulator system for FDA 510(k) clearance in early February, aiming to complete the regulatory puzzle for Imricor’s full electrophysiology ecosystem. The company also filed for a paediatric label expansion for NorthStar under the FDA’s Special 510(k) pathway, targeting over 250 children’s hospitals across the US and anticipating clearance within the current quarter. This move could unlock a significant early commercial entry point, especially given the clinical importance of reducing radiation exposure in paediatric settings. This regulatory momentum follows the company’s recent FDA 510(k) clearance secured and FDA submission of Advantage-MR.

Clinical Trial Expansion Strengthens Validation and Market Access

On the clinical front, Imricor substantially expanded enrolment capacity for its VISABL-AFL trial by onboarding Virginia Commonwealth University and Oklahoma Heart Institute, two high-volume US centres performing over 800 atrial flutter ablations annually. This expansion not only increases patient recruitment potential but also deepens relationships with key electrophysiology opinion leaders, reinforcing the company’s US clinical footprint ahead of anticipated approvals and commercial rollout.

In Europe, the addition of Prague’s Na Homolce hospital to the VISABL-VT trial under the guidance of renowned electrophysiologists Dr Vivek Reddy and Prof. Petr Neužil further bolsters Imricor’s clinical validation efforts in ventricular tachycardia ablations. Na Homolce’s volume of approximately 3,500 catheterisation procedures annually positions it as a crucial site for generating robust clinical data to support market adoption. These clinical developments build on the ongoing VISABL-AFL and VISABL-VT clinical trials that underpin Imricor’s US approval strategy.

Commercial Pipeline Gains Traction with Growing Market Interest

Commercially, the quarter saw continued progress converting pipeline opportunities into active installations and customer engagements. In the US, NorthStar’s FDA clearance has generated meaningful attention, particularly in both adult electrophysiology and paediatric markets where the elimination of ionising radiation is a compelling proposition. In Europe and the Middle East, Imricor is advancing site activations and regional expansion, underscored by the iCMR summit in Riyadh that drew around 100 stakeholders keen on adopting the technology.

Financials Reflect Strategic Investments and Transition to In-House Production

Imricor reported a total operating cash outflow of US$7.8 million in Q1 CY26, up from US$5.2 million in the prior quarter. This included a one-off investment in 40 RF-5000 generators to support initial customer sites as the company transitions capital equipment manufacturing in-house, alongside audit and legal expenses related to its SEC Form 10 registration. Underlying operating cash outflows excluding these one-offs were US$5.9 million, reflecting increased activity across R&D, manufacturing, marketing, and staff costs.

Cash receipts improved 140% quarter-on-quarter to US$62,000 but remain modest due to non-revenue generating clinical trial enrolments. Imricor expects operating cash outflows to normalise to approximately US$6 million in Q2 CY26. The company’s cash and short-term investments stood at US$32.9 million (A$48 million) as of 31 March, providing a runway of over four quarters based on current burn rates. This financial position builds on the strong liquidity following a recent Form 10 registration with the SEC and capital raises in prior periods.